Our study showed that EO-CRC expressed positive HER2/neu expression in a higher proportion of cases (27.1%), compared with LO-CRC, which expressed HER2/neu positivity in 13.2% of cases. The gene discussed is ERBB2; the disease is colorectal carcinoma.